Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.54 USD | -5.16% | -8.61% | -9.05% |
Jun. 07 | LifeMD Files for $150 Million Mixed Shelf | MT |
Jun. 05 | KeyBanc Initiates LifeMD at Overweight With $12 Price Target, Cites 'Strong Top & Bottom-Line Growth' | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 6.082 | 137.1 | 118.4 | 61.01 | 325 | 318.9 | - | - |
Enterprise Value (EV) 1 | 6.082 | 137.1 | 77.74 | 61.01 | 325 | 318.9 | 318.9 | 318.9 |
P/E ratio | -1.64 x | -1.47 x | -1.69 x | -1.24 x | -11.8 x | -28.2 x | 57.1 x | - |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 1.55 x | 1.25 x | 1.08 x |
EV / Revenue | - | 3.68 x | 1.27 x | 0.51 x | 2.13 x | 1.55 x | 1.25 x | 1.08 x |
EV / EBITDA | - | -8.43 x | -3.09 x | -4.16 x | 27.1 x | 16.4 x | 10.2 x | 7.25 x |
EV / FCF | - | -11.3 x | -3.25 x | - | - | 48.5 x | 23.7 x | - |
FCF Yield | - | -8.85% | -30.8% | - | - | 2.06% | 4.22% | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,578 | 20,992 | 30,593 | 31,450 | 39,203 | 42,290 | - | - |
Reference price 2 | 0.5750 | 6.530 | 3.870 | 1.940 | 8.290 | 7.540 | 7.540 | 7.540 |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 37.29 | 92.88 | 119 | 152.5 | 206 | 254.7 | 295.3 |
EBITDA 1 | - | -16.26 | -38.28 | -14.66 | 11.98 | 19.39 | 31.41 | 44 |
EBIT 1 | - | -57.82 | -54.3 | -43.45 | -14.49 | -4.856 | 12.79 | - |
Operating Margin | - | -155.04% | -58.47% | -36.5% | -9.5% | -2.36% | 5.02% | - |
Earnings before Tax (EBT) 1 | - | -60.4 | -61.32 | -44.66 | -17.41 | -8.544 | 7.641 | -1.7 |
Net income 1 | -3.137 | -63.36 | -61.77 | -48.64 | -23.7 | -12.14 | 3.836 | -1.7 |
Net margin | - | -169.9% | -66.51% | -40.86% | -15.54% | -5.89% | 1.51% | -0.58% |
EPS 2 | -0.3500 | -4.440 | -2.290 | -1.570 | -0.7000 | -0.2675 | 0.1320 | - |
Free Cash Flow 1 | - | -12.13 | -36.47 | - | - | 6.576 | 13.46 | - |
FCF margin | - | -32.53% | -39.26% | - | - | 3.19% | 5.28% | - |
FCF Conversion (EBITDA) | - | - | - | - | - | 33.92% | 42.85% | - |
FCF Conversion (Net income) | - | - | - | - | - | - | 350.77% | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 27.42 | 29.04 | 30.46 | 31.41 | 28.12 | 33.13 | 35.95 | 38.61 | 44.86 | 44.14 | 48.18 | 52.94 | 60.02 | 56.56 | 59.92 |
EBITDA 1 | -8.219 | -7.584 | -6.927 | -1 | 0.6307 | 2 | 1.733 | 2.775 | 5.489 | 0.4468 | 2.529 | 6.336 | 10.09 | 5.143 | 6.324 |
EBIT 1 | -13.66 | -13.11 | -15.64 | -6.818 | -10.37 | -2.853 | -4.896 | -4.569 | -2.172 | -6.171 | -3.064 | 0.0094 | 4.049 | -2.69 | -0.8875 |
Operating Margin | -49.84% | -45.13% | -51.35% | -21.7% | -36.88% | -8.61% | -13.62% | -11.83% | -4.84% | -13.98% | -6.36% | 0.02% | 6.75% | -4.76% | -1.48% |
Earnings before Tax (EBT) 1 | -18 | -13.27 | -12.97 | -7.198 | -11.21 | -3.442 | -5.891 | -5.283 | -2.794 | -6.649 | -4.075 | -0.7863 | 2.722 | -3.167 | -1.765 |
Net income 1 | -18.98 | -14.08 | -13.8 | -8.058 | -12.71 | -4.785 | -7.51 | -6.899 | -4.509 | -7.545 | -5.094 | -1.71 | 1.879 | -4.121 | -2.72 |
Net margin | -69.24% | -48.47% | -45.29% | -25.65% | -45.21% | -14.44% | -20.89% | -17.87% | -10.05% | -17.09% | -10.57% | -3.23% | 3.13% | -7.29% | -4.54% |
EPS 2 | -0.6300 | -0.4600 | -0.4500 | -0.2600 | -0.4000 | -0.1500 | -0.2300 | -0.2000 | -0.1200 | -0.1900 | -0.1260 | -0.0420 | 0.0620 | -0.0700 | -0.1000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/7/22 | 5/13/22 | 8/11/22 | 11/10/22 | 3/22/23 | 5/12/23 | 8/9/23 | 11/8/23 | 3/11/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | 40.7 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -12.1 | -36.5 | - | - | 6.58 | 13.5 | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | 3.38 | - | - | 0.5 | 0.44 | - |
Capex / Sales | - | - | 3.64% | - | - | 0.24% | 0.17% | - |
Announcement Date | 3/30/20 | 3/29/21 | 3/7/22 | 3/22/23 | 3/11/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.05% | 319M | |
-4.87% | 29.6B | |
+31.35% | 8.65B | |
+34.03% | 4.42B | |
-28.91% | 2.69B | |
-9.91% | 1.6B | |
-21.02% | 1.36B | |
-35.78% | 1.1B | |
+3.28% | 924M | |
-43.36% | 791M |
- Stock Market
- Equities
- LFMD Stock
- Financials LifeMD, Inc.